PL3978522T3 - Ludzkie przeciwciała przeciwko fel d1 i sposoby ich stosowania - Google Patents
Ludzkie przeciwciała przeciwko fel d1 i sposoby ich stosowaniaInfo
- Publication number
- PL3978522T3 PL3978522T3 PL21194412.9T PL21194412T PL3978522T3 PL 3978522 T3 PL3978522 T3 PL 3978522T3 PL 21194412 T PL21194412 T PL 21194412T PL 3978522 T3 PL3978522 T3 PL 3978522T3
- Authority
- PL
- Poland
- Prior art keywords
- fel
- antibodies
- methods
- human anti
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642083P | 2012-05-03 | 2012-05-03 | |
| US201261718044P | 2012-10-24 | 2012-10-24 | |
| US201361783312P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3978522T3 true PL3978522T3 (pl) | 2026-01-05 |
Family
ID=48326501
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21194412.9T PL3978522T3 (pl) | 2012-05-03 | 2013-05-02 | Ludzkie przeciwciała przeciwko fel d1 i sposoby ich stosowania |
| PL19218187T PL3660047T3 (pl) | 2012-05-03 | 2013-05-02 | Ludzkie przeciwciała przeciwko fel d1 i sposoby ich użycia |
| PL13721544T PL2844672T3 (pl) | 2012-05-03 | 2013-05-02 | Ludzkie przeciwciała dla Fel d1 i sposoby ich stosowania |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19218187T PL3660047T3 (pl) | 2012-05-03 | 2013-05-02 | Ludzkie przeciwciała przeciwko fel d1 i sposoby ich użycia |
| PL13721544T PL2844672T3 (pl) | 2012-05-03 | 2013-05-02 | Ludzkie przeciwciała dla Fel d1 i sposoby ich stosowania |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US9079948B2 (pl) |
| EP (4) | EP3978522B1 (pl) |
| JP (2) | JP6400569B2 (pl) |
| KR (1) | KR102185516B1 (pl) |
| CN (2) | CN110240651B (pl) |
| AR (1) | AR090914A1 (pl) |
| AU (2) | AU2013256251C1 (pl) |
| BR (2) | BR112014026852B1 (pl) |
| CA (1) | CA2871077C (pl) |
| CY (2) | CY1124023T1 (pl) |
| DK (2) | DK2844672T3 (pl) |
| ES (3) | ES2780392T3 (pl) |
| FI (1) | FI3978522T3 (pl) |
| HR (3) | HRP20200652T1 (pl) |
| HU (2) | HUE049440T2 (pl) |
| IL (1) | IL235121B (pl) |
| IN (1) | IN2014DN08767A (pl) |
| JO (1) | JO3820B1 (pl) |
| LT (3) | LT3660047T (pl) |
| MX (2) | MX377634B (pl) |
| MY (3) | MY195564A (pl) |
| NZ (2) | NZ733480A (pl) |
| PL (3) | PL3978522T3 (pl) |
| PT (3) | PT2844672T (pl) |
| RS (3) | RS67417B1 (pl) |
| RU (1) | RU2658491C2 (pl) |
| SG (3) | SG11201406748QA (pl) |
| SI (3) | SI3978522T1 (pl) |
| SM (3) | SMT202000241T1 (pl) |
| TW (2) | TWI644921B (pl) |
| UY (1) | UY34782A (pl) |
| WO (1) | WO2013166236A1 (pl) |
| ZA (3) | ZA201407302B (pl) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| NZ597481A (en) | 2009-07-08 | 2013-10-25 | Kymab Ltd | Animal models and therapeutic molecules |
| EP3839049A3 (en) | 2011-09-19 | 2021-10-20 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| JO3820B1 (ar) * | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| CA2922113C (en) * | 2013-08-23 | 2023-05-23 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| DE112014004537T5 (de) | 2013-10-01 | 2016-07-21 | Kymab Limited | Tiermodelle und therapeutische Moleküle |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| RS60739B1 (sr) | 2014-11-17 | 2020-09-30 | Regeneron Pharma | Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela |
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| TWI899515B (zh) | 2015-08-04 | 2025-10-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| CN108025059B (zh) * | 2015-09-08 | 2022-09-09 | 苏黎世大学 | 抗猫过敏的组合物 |
| EP3445783A2 (en) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| EP3558347B1 (en) * | 2016-12-22 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| CA3049828A1 (en) | 2017-01-24 | 2018-08-02 | Societe Des Produits Nestle S.A. | Compositions comprising anti-fel d1 antibodies and methods for reducing at least one symptom of human allergy to cats |
| CN110914293B (zh) | 2017-07-06 | 2024-08-13 | 里珍纳龙药品有限公司 | 用于制备糖蛋白的细胞培养工艺 |
| CA3084059A1 (en) | 2017-12-22 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| BR112020013336A2 (pt) | 2018-01-31 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário. |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| KR20260004591A (ko) | 2018-02-28 | 2026-01-08 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 오염물질을 확인하기 위한 시스템 및 방법 |
| IL277264B2 (en) | 2018-03-19 | 2024-03-01 | Regeneron Pharma | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| CN112166119B (zh) * | 2018-05-18 | 2024-12-20 | 陈扎克伯格生物中心旧金山公司 | 从人中分离过敏原特异性抗体的方法及其用途 |
| AU2019329686A1 (en) | 2018-08-27 | 2020-12-03 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| AU2019333047A1 (en) | 2018-08-30 | 2020-12-03 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| US11579150B2 (en) | 2019-01-16 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
| KR20220007586A (ko) | 2019-05-13 | 2022-01-18 | 리제너론 파마슈티칼스 인코포레이티드 | 개선된 경쟁적 리간드 결합 검정 |
| CN114667450B (zh) | 2019-09-24 | 2025-05-02 | 里珍纳龙药品有限公司 | 用于色谱介质的使用和再生的系统及方法 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| BR112022009974A2 (pt) | 2019-11-25 | 2022-08-16 | Regeneron Pharma | Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica |
| CA3165060C (en) | 2020-01-21 | 2023-06-20 | Yiming Zhao | Deglycosylation methods for electrophoresis of glycosylated proteins |
| US20220064270A1 (en) | 2020-08-26 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| TW202432837A (zh) | 2020-08-31 | 2024-08-16 | 美商再生元醫藥公司 | 用以改良細胞培養效能及減少天冬醯胺序列變異之天冬醯胺饋料策略 |
| WO2022115588A1 (en) | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| CN116710124A (zh) | 2020-12-17 | 2023-09-05 | 瑞泽恩制药公司 | 包封蛋白质的微凝胶的制造 |
| AU2022209730A1 (en) | 2021-01-20 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| BR112023017442A2 (pt) | 2021-03-03 | 2023-09-26 | Regeneron Pharma | Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica |
| WO2022192625A1 (en) | 2021-03-11 | 2022-09-15 | IgGenix, Inc. | Methods and systems for predicting allergic response |
| BR112023018665A2 (pt) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | Métodos e sistemas para desenvolvimento de protocolos de mistura |
| KR20240015646A (ko) | 2021-06-01 | 2024-02-05 | 리제너론 파마슈티칼스 인코포레이티드 | 마이크로칩 모세관 전기영동 분석 및 시약 |
| US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
| CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
| US20230110811A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | pH METER CALIBRATION AND CORRECTION |
| IL311245A (en) | 2021-10-07 | 2024-05-01 | Regeneron Pharma | Systems and methods for pH modeling and control |
| EP4423018A1 (en) | 2021-10-26 | 2024-09-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| CN114113278B (zh) * | 2021-11-24 | 2024-08-02 | 中国计量科学研究院 | 一种基于质谱的体外诊断试剂抗体的表位定位方法 |
| CN118660719A (zh) * | 2021-12-08 | 2024-09-17 | 艾吉尼克斯公司 | 用于过敏症疗法的组合 |
| AU2023233590A1 (en) | 2022-03-18 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| CA3251374A1 (en) | 2022-06-23 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | METHODS FOR IDENTIFYING AND EVALUATING GENETIC SIGNATURES OF CAT ALLERGY IN A SUBJECT BY DETERMINING A STRATIFIED SCORE BASED ON GENE EXPRESSION. |
| WO2024130048A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| EP4655595A1 (en) | 2023-01-25 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| US20240255519A1 (en) | 2023-02-01 | 2024-08-01 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| WO2024178213A2 (en) | 2023-02-22 | 2024-08-29 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| WO2024182636A1 (en) | 2023-03-01 | 2024-09-06 | Regeneron Pharmaceuticals, Inc. | Anti-fel d1 antibody formulations |
| CN121241065A (zh) | 2023-03-31 | 2025-12-30 | 爱尔开-阿贝优公司 | 适用于治疗树木花粉过敏的过敏原结合抗体 |
| US20240366471A1 (en) | 2023-05-01 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| CN117004650B (zh) * | 2023-06-25 | 2024-05-14 | 山东立菲生物产业有限公司 | 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用 |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20250095773A1 (en) | 2023-09-18 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| WO2025072597A2 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| CN117069865B (zh) * | 2023-10-12 | 2024-03-01 | 中国农业科学院饲料研究所 | 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备 |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| TW202535934A (zh) | 2023-11-02 | 2025-09-16 | 美商再生元醫藥公司 | 利用應力來降低脂酶活性的方法 |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| CN117964767B (zh) * | 2024-03-29 | 2024-08-06 | 北京恩泽康泰生物科技有限公司 | 抗rage抗体、细胞外囊泡及其制备方法和应用 |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5512283A (en) | 1990-07-06 | 1996-04-30 | Allergene, Inc. | Methods for the selective suppression of an immune response to dust mite der Pi |
| AU3591793A (en) * | 1992-01-21 | 1993-08-03 | Immulogic Pharmaceutical Corporation | Methods for using histamine derivatives as immunomodulators and in immunotherapeutics |
| AU5958494A (en) | 1992-12-21 | 1994-07-19 | Tanox Biosystems, Inc. | Allergen-specific iga monoclonal antibodies and related products for allergy treatment |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| RU2414239C2 (ru) * | 2005-03-18 | 2011-03-20 | Цитос Биотехнологи Аг | Белки, слитые с кошачьим аллергеном, и их применение |
| US7566456B2 (en) * | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
| GB0513878D0 (en) * | 2005-07-06 | 2005-08-10 | Mars Inc | Cat allergen |
| WO2007065633A1 (en) | 2005-12-05 | 2007-06-14 | Imvision Ag | Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules |
| WO2007113633A2 (en) * | 2006-04-03 | 2007-10-11 | Pfizer Products Inc. | Immunogenic compositions comprising cat allergen fel dl |
| SI2041177T1 (sl) | 2006-06-02 | 2012-03-30 | Regeneron Pharma | Visoko afinitetna protitelesa za humani IL receptor |
| AT503690A1 (de) | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP1921142A1 (en) * | 2006-11-07 | 2008-05-14 | Cytos Biotechnology AG | Selection of human monoclonal antibodies by eukaryotic cell display |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| CA2681974C (en) * | 2007-03-29 | 2019-12-31 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2666787B1 (en) * | 2007-05-31 | 2022-02-09 | Genmab A/S | STABLE IgG4 ANTIBODIES |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| DK2162133T3 (en) * | 2007-07-09 | 2016-10-24 | Nestec Sa | Approaches to reduce allergies caused by environmental allergens |
| JP5632744B2 (ja) | 2007-08-10 | 2014-11-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト神経成長因子に対する高親和性ヒト抗体 |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| EP3354280B1 (en) | 2010-10-06 | 2020-07-29 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| CA2922113C (en) | 2013-08-23 | 2023-05-23 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| EP3558347B1 (en) | 2016-12-22 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
-
2013
- 2013-05-01 JO JOP/2013/0131A patent/JO3820B1/ar active
- 2013-05-02 HR HRP20200652TT patent/HRP20200652T1/hr unknown
- 2013-05-02 MY MYPI2020006733A patent/MY195564A/en unknown
- 2013-05-02 HR HRP20251429TT patent/HRP20251429T1/hr unknown
- 2013-05-02 HU HUE13721544A patent/HUE049440T2/hu unknown
- 2013-05-02 NZ NZ733480A patent/NZ733480A/en unknown
- 2013-05-02 PL PL21194412.9T patent/PL3978522T3/pl unknown
- 2013-05-02 SM SM20200241T patent/SMT202000241T1/it unknown
- 2013-05-02 SM SM20250396T patent/SMT202500396T1/it unknown
- 2013-05-02 HR HRP20211932TT patent/HRP20211932T1/hr unknown
- 2013-05-02 SI SI201332111T patent/SI3978522T1/sl unknown
- 2013-05-02 SI SI201331698T patent/SI2844672T1/sl unknown
- 2013-05-02 BR BR112014026852-5A patent/BR112014026852B1/pt active IP Right Grant
- 2013-05-02 RS RS20251155A patent/RS67417B1/sr unknown
- 2013-05-02 CA CA2871077A patent/CA2871077C/en active Active
- 2013-05-02 EP EP21194412.9A patent/EP3978522B1/en active Active
- 2013-05-02 DK DK13721544.8T patent/DK2844672T3/da active
- 2013-05-02 PL PL19218187T patent/PL3660047T3/pl unknown
- 2013-05-02 MX MX2014013371A patent/MX377634B/es active IP Right Grant
- 2013-05-02 AR ARP130101494 patent/AR090914A1/es unknown
- 2013-05-02 ES ES13721544T patent/ES2780392T3/es active Active
- 2013-05-02 CN CN201910294004.8A patent/CN110240651B/zh active Active
- 2013-05-02 FI FIEP21194412.9T patent/FI3978522T3/fi active
- 2013-05-02 CN CN201380035000.9A patent/CN104411719B/zh active Active
- 2013-05-02 AU AU2013256251A patent/AU2013256251C1/en active Active
- 2013-05-02 EP EP19218187.3A patent/EP3660047B1/en active Active
- 2013-05-02 EP EP25194366.8A patent/EP4653056A2/en active Pending
- 2013-05-02 DK DK21194412.9T patent/DK3978522T3/da active
- 2013-05-02 PL PL13721544T patent/PL2844672T3/pl unknown
- 2013-05-02 ES ES19218187T patent/ES2898372T3/es active Active
- 2013-05-02 LT LTEP19218187.3T patent/LT3660047T/lt unknown
- 2013-05-02 LT LTEP21194412.9T patent/LT3978522T/lt unknown
- 2013-05-02 MY MYPI2017701565A patent/MY181422A/en unknown
- 2013-05-02 SI SI201331935T patent/SI3660047T1/sl unknown
- 2013-05-02 ES ES21194412T patent/ES3049982T3/es active Active
- 2013-05-02 PT PT137215448T patent/PT2844672T/pt unknown
- 2013-05-02 HU HUE19218187A patent/HUE057062T2/hu unknown
- 2013-05-02 WO PCT/US2013/039192 patent/WO2013166236A1/en not_active Ceased
- 2013-05-02 NZ NZ701124A patent/NZ701124A/en unknown
- 2013-05-02 MY MYPI2014002857A patent/MY164101A/en unknown
- 2013-05-02 US US13/875,401 patent/US9079948B2/en active Active
- 2013-05-02 SM SM20220014T patent/SMT202200014T1/it unknown
- 2013-05-02 SG SG11201406748QA patent/SG11201406748QA/en unknown
- 2013-05-02 BR BR122019023685-2A patent/BR122019023685B1/pt active IP Right Grant
- 2013-05-02 SG SG10201608378UA patent/SG10201608378UA/en unknown
- 2013-05-02 SG SG10202102919XA patent/SG10202102919XA/en unknown
- 2013-05-02 RS RS20211475A patent/RS62636B1/sr unknown
- 2013-05-02 RS RS20200539A patent/RS60282B1/sr unknown
- 2013-05-02 JP JP2015510445A patent/JP6400569B2/ja active Active
- 2013-05-02 TW TW102115645A patent/TWI644921B/zh active
- 2013-05-02 EP EP13721544.8A patent/EP2844672B1/en active Active
- 2013-05-02 PT PT192181873T patent/PT3660047T/pt unknown
- 2013-05-02 TW TW106119738A patent/TW201803901A/zh unknown
- 2013-05-02 RU RU2014148502A patent/RU2658491C2/ru active
- 2013-05-02 KR KR1020147033137A patent/KR102185516B1/ko active Active
- 2013-05-02 LT LTEP13721544.8T patent/LT2844672T/lt unknown
- 2013-05-02 IN IN8767DEN2014 patent/IN2014DN08767A/en unknown
- 2013-05-02 PT PT211944129T patent/PT3978522T/pt unknown
- 2013-05-03 UY UY34782A patent/UY34782A/es active IP Right Grant
-
2014
- 2014-10-08 ZA ZA2014/07302A patent/ZA201407302B/en unknown
- 2014-10-19 IL IL235121A patent/IL235121B/en active IP Right Grant
- 2014-11-03 MX MX2020003864A patent/MX2020003864A/es unknown
-
2015
- 2015-06-05 US US14/732,578 patent/US9475869B2/en active Active
-
2016
- 2016-09-13 US US15/263,848 patent/US10047152B2/en active Active
-
2017
- 2017-01-26 US US15/416,176 patent/US10047153B2/en active Active
- 2017-06-14 JP JP2017116808A patent/JP6603269B2/ja active Active
-
2018
- 2018-05-03 AU AU2018203087A patent/AU2018203087B9/en active Active
- 2018-07-05 US US16/028,275 patent/US11174305B2/en active Active
-
2020
- 2020-05-04 CY CY20201100408T patent/CY1124023T1/el unknown
- 2020-08-25 ZA ZA2020/05273A patent/ZA202005273B/en unknown
-
2021
- 2021-10-13 US US17/500,418 patent/US12252530B2/en active Active
- 2021-12-20 CY CY20211101115T patent/CY1124819T1/el unknown
-
2022
- 2022-03-09 ZA ZA2022/02846A patent/ZA202202846B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3978522T3 (pl) | Ludzkie przeciwciała przeciwko fel d1 i sposoby ich stosowania | |
| IL263466A (en) | Anti-cd3 antibodies and methods of use | |
| PL2812443T3 (pl) | Przeciwciała CD47 i sposoby ich zastosowania | |
| CL2015001321A1 (es) | Anticuerpos anti-ceacam5 y usos de éstos | |
| DK2806892T3 (da) | Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser | |
| IL229469B (en) | Human immunodeficiency virus neutralizing antibodies and methods of use therof | |
| GB201223276D0 (en) | Antibodies and methods of producing same | |
| IL232055A0 (en) | Anti-htra1 antibodies and methods of use | |
| IL236738A0 (en) | Human antibodies to gfra3 and methods of using them | |
| ZA201404675B (en) | Anti-lrp5 antibodies and methods of use | |
| SG11201502757QA (en) | Anti-c16orf54 antibodies and methods of use thereof | |
| EP2870180C0 (en) | ANTI-BIOTIN ANTIBODIES AND METHODS OF USE | |
| CL2014002789A1 (es) | Terapia de combinación de anticuerpos anti-mif y glucocorticoides | |
| FI20115583A0 (fi) | Rakennusjärjestely ja -menetelmä |